邁克生物(300463.SZ)半年度淨利潤預增70%-80%
格隆匯7月14日丨邁克生物(300463.SZ)公佈,預計2021年半年度實現營業收入188821.02萬元-203345.72萬元,同比增長30%-40%;歸屬於上市公司股東的淨利潤52747.12萬元-55849.89萬元,同比增長70%-80%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤52034.02萬元-55094.84萬元,同比增長70%-80%。
隨着國內疫情得到有效控制,國內經濟復甦,報吿期內公司常規生化、免疫、臨檢等平台檢測產品的銷售快速恢復並實現較高增長。公司經營管理層根據外部環境變化和內部發展需求積極調整經營策略,持續補充和完善自主產品種類,提速各平台自主儀器及流水線產品裝機,繼續推進國內銷售渠道的建設與完善,加大海外市場拓展力度,不斷提升綜合服務能力。報吿期內,公司憑藉豐富的產品、優質的服務獲得國內外終端客户的認可,促使公司本報吿期的經營業績較上年同期實現大幅度增長。
報吿期內,預計非經常性損益對淨利潤的影響為650萬元左右,主要系收到政府補助。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.